Infectious Canine Hepatitis

Infectious canine hepatitis is an acute viral disease caused by canine adenovirus type 1 (CAV-1). The virus has a particular affinity for the liver, kidneys, and vascular endothelium, causing widespread inflammation and organ damage. First described by the Swedish veterinarian Sven Rubarth in 1947, this disease was once a major cause of death in domestic dogs worldwide before the development of effective vaccines.

The disease can range from a subclinical or mild infection to a peracute, rapidly fatal illness. In its most severe form, infectious canine hepatitis can kill a dog within hours of the first clinical signs appearing, making it one of the more dangerous viral diseases that can affect unvaccinated canines. The virus is highly stable in the environment and resistant to many common disinfectants, contributing to its ability to persist and spread.

While the incidence of infectious canine hepatitis has declined dramatically in regions with widespread vaccination programs, it remains a significant threat in areas with low vaccination rates. The disease continues to circulate in wildlife reservoirs, particularly foxes, wolves, and coyotes, which can serve as sources of infection for domestic dogs. Understanding this disease is critical for all dog owners, as prevention through vaccination remains the single most effective strategy against this potentially devastating infection.

Veterinary science has made considerable advances in understanding the pathophysiology and epidemiology of CAV-1 infection. Modern diagnostic techniques allow for rapid identification of the virus, and supportive care protocols have improved outcomes for dogs that do contract the disease. Nevertheless, there is no specific antiviral treatment, and severely affected dogs may succumb despite aggressive intervention.

Infectious canine hepatitis is caused exclusively by canine adenovirus type 1 (CAV-1), a non-enveloped, double-stranded DNA virus belonging to the family Adenoviridae. The virus is highly resistant to environmental degradation and can survive outside the host for weeks to months under favorable conditions. It is resistant to lipid solvents such as ether and chloroform due to its non-enveloped structure, and it can withstand a wide range of pH levels and temperatures.

Transmission occurs primarily through the oronasal route when a susceptible dog ingests or inhales material contaminated with the virus. The most common sources of infection include urine, feces, saliva, and nasal secretions from infected animals. Recovered dogs can shed the virus in their urine for six to nine months after infection, making them a persistent source of environmental contamination even when they appear clinically healthy.

Fomites such as food bowls, bedding, crates, and the clothing or hands of people who have handled infected animals can also serve as vectors for viral transmission. The virus can persist on contaminated surfaces for weeks, particularly in cool, shaded environments. Ectoparasites, including ticks and mosquitoes, have also been implicated as potential mechanical vectors, though this route of transmission is considered less significant than direct contact or environmental exposure.

Wildlife reservoirs play an important role in the epidemiology of CAV-1. Foxes, wolves, coyotes, bears, and other wild canids can harbor and shed the virus, maintaining it in the environment even in areas where domestic dog vaccination rates are high. Dogs that have contact with wildlife or frequent areas where wildlife is present may be at increased risk of exposure.

The clinical presentation of infectious canine hepatitis varies considerably depending on the age and immune status of the affected dog, the viral dose received, and the strain of CAV-1 involved. The incubation period is typically four to seven days following exposure. In peracute cases, dogs may be found dead with little to no preceding clinical signs, a presentation most commonly seen in very young puppies.

Acute infections typically begin with a sudden onset of fever, often reaching 104 to 106 degrees Fahrenheit (40 to 41 degrees Celsius). Dogs commonly display lethargy, depression, loss of appetite, and increased thirst. Tonsillitis and pharyngitis are frequently among the first observable signs. As the disease progresses, vomiting, diarrhea (which may be bloody), and abdominal pain become apparent, with dogs often showing reluctance to move and a tucked-up posture due to hepatic and abdominal discomfort.

One of the hallmark features of infectious canine hepatitis is a condition known as "hepatitis blue eye" or anterior uveitis, which manifests as a bilateral or unilateral corneal opacity giving the eye a distinctive blue or cloudy appearance. This sign typically develops during the recovery phase, approximately one to two weeks after infection, and results from immune complex deposition in the cornea. While often self-resolving, it can occasionally lead to permanent corneal damage or secondary glaucoma.

Hemorrhagic manifestations are common in moderate to severe cases due to the virus's effect on vascular endothelium and its impact on hepatic synthesis of clotting factors. Petechial and ecchymotic hemorrhages may be observed on the gums, skin, and serosal surfaces. Subcutaneous edema, particularly of the head and neck, can occur. Enlarged, painful lymph nodes and hepatomegaly are frequently detected on physical examination. In severe cases, dogs may develop disseminated intravascular coagulation (DIC), a life-threatening coagulopathy.

Mild or subclinical infections are also recognized, particularly in partially immune dogs. These animals may show only a transient fever, mild lethargy, or slight tonsillitis before recovering without specific treatment. However, even mildly affected dogs may shed the virus and contribute to environmental contamination.

Diagnosing infectious canine hepatitis requires a combination of clinical assessment, laboratory testing, and, in some cases, post-mortem examination. The presenting signs of fever, tonsillitis, hepatomegaly, and corneal edema in an unvaccinated dog should raise strong suspicion for ICH, though several other diseases can produce similar clinical pictures.

Blood work typically reveals a characteristic pattern. A complete blood count often shows an initial leukopenia (low white blood cell count) during the viremic phase, followed by leukocytosis during recovery. Thrombocytopenia (low platelet count) is common and correlates with the hemorrhagic tendencies seen clinically. Serum biochemistry panels usually demonstrate markedly elevated liver enzymes, including alanine aminotransferase (ALT) and alkaline phosphatase (ALP), reflecting hepatocellular damage. Bilirubin levels may be elevated in severely affected dogs, and coagulation panels often reveal prolonged clotting times.

Definitive diagnosis relies on virus isolation, detection of viral antigen, or identification of viral DNA. Polymerase chain reaction (PCR) testing is the most sensitive and specific method and can detect CAV-1 DNA in blood, urine, oropharyngeal swabs, or tissue samples. Immunofluorescence testing on liver biopsy or necropsy samples can also confirm the presence of viral antigen. Serological testing, including paired serum titers demonstrating a fourfold rise in anti-CAV-1 antibodies, can provide retrospective confirmation of infection.

Differential diagnoses that must be considered include canine distemper, leptospirosis, canine herpesvirus infection, toxic hepatopathy, copper storage disease, and other causes of acute liver failure. Careful integration of clinical findings, laboratory data, and epidemiological information is essential for arriving at an accurate diagnosis. Abdominal ultrasound may reveal hepatomegaly, altered hepatic echogenicity, gall bladder wall edema, and peritoneal effusion, findings that support a diagnosis of hepatitis but are not specific to CAV-1.

Post-mortem examination in fatal cases reveals characteristic findings including an enlarged, congested liver with a distinctive fibrinous exudate on the hepatic surface, edematous gallbladder wall, serosal hemorrhages, and swollen lymph nodes. Histologically, the presence of intranuclear inclusion bodies in hepatocytes is considered pathognomonic for CAV-1 infection.

There is no specific antiviral therapy available for infectious canine hepatitis. Treatment is entirely supportive and symptomatic, aimed at maintaining the dog through the acute phase of illness while the immune system mounts a response against the virus. The prognosis depends heavily on the severity of disease at presentation and the promptness and quality of supportive care provided.

Intravenous fluid therapy forms the cornerstone of treatment, correcting dehydration, maintaining electrolyte balance, and supporting renal perfusion. Crystalloid solutions such as lactated Ringer's solution or normal saline are commonly used, with the rate and volume adjusted based on the degree of dehydration and ongoing losses. Colloid solutions may be necessary in dogs with significant protein loss or hypoalbuminemia resulting from hepatic dysfunction.

Antiemetic medications are administered to control vomiting, and gastroprotectants such as sucralfate, famotidine, or omeprazole may be used to protect the gastrointestinal mucosa. Broad-spectrum antibiotics are indicated to prevent or treat secondary bacterial infections, as the compromised hepatic and immune function leaves dogs vulnerable to opportunistic pathogens. Hepatoprotective agents such as S-adenosylmethionine (SAMe), silymarin, and ursodiol may be used to support liver recovery.

In dogs with coagulation abnormalities or active hemorrhage, fresh frozen plasma transfusions may be necessary to replace depleted clotting factors. Whole blood transfusions may be required in cases of severe anemia. Vitamin K1 supplementation can support coagulation factor synthesis. Dogs with disseminated intravascular coagulation require aggressive management including heparin therapy in some protocols, though the treatment of DIC remains challenging regardless of the underlying cause.

Hospitalized dogs should be isolated to prevent transmission to other patients, and strict hygiene protocols must be observed by veterinary staff. Monitoring during the recovery phase includes serial blood work to track liver enzyme trends, coagulation parameters, and blood cell counts. Most dogs that survive the acute phase begin to improve within seven to ten days, though full hepatic recovery may take weeks to months.

The prognosis for infectious canine hepatitis is highly variable and depends on the form and severity of the disease. Dogs with peracute infections, particularly very young puppies, have a poor prognosis, with mortality rates approaching 100 percent in some reports. In contrast, dogs with mild or subclinical infections typically recover fully without complications.

For dogs with moderate to severe acute infections that receive appropriate supportive care, survival rates are generally favorable, with many studies reporting recovery in approximately 70 to 80 percent of treated cases. The critical period is typically the first 48 to 72 hours following the onset of clinical signs. Dogs that survive this initial period and show stabilization or improvement in their clinical status and laboratory parameters generally go on to make a full recovery.

The development of "blue eye" during recovery, while alarming in appearance, is generally self-limiting and resolves within one to three weeks in most cases. However, a small percentage of dogs may develop chronic corneal opacity, secondary glaucoma, or other permanent ocular complications requiring ongoing ophthalmologic management.

Long-term hepatic consequences are possible in dogs that have experienced severe infection. Chronic active hepatitis and hepatic fibrosis have been documented in some dogs following recovery from acute ICH. These dogs may require long-term monitoring with periodic liver enzyme assessments, and some may eventually develop signs of chronic liver disease. Dogs that develop chronic interstitial nephritis as a sequel to infection may also require ongoing renal monitoring.

Dogs that recover from infectious canine hepatitis typically develop strong, long-lasting immunity to reinfection. However, as mentioned previously, recovered dogs can shed the virus in their urine for an extended period, posing a risk to susceptible animals in their environment. Owners should be counseled about this shedding period and advised to minimize contact between recovered dogs and unvaccinated animals during this time.

Vaccination is the primary and most effective method of preventing infectious canine hepatitis. The canine adenovirus type 2 (CAV-2) vaccine is used rather than a CAV-1 vaccine because it provides cross-protective immunity against CAV-1 while avoiding the side effects associated with the original CAV-1 vaccines, particularly post-vaccinal "blue eye" and renal lesions. The CAV-2 vaccine is typically included in the core combination vaccines commonly referred to as DHPP or DA2PP.

Puppies should receive their initial vaccination series beginning at six to eight weeks of age, with booster doses administered every three to four weeks until the puppy is at least 16 weeks old. This schedule ensures that maternal antibodies, which can interfere with vaccine efficacy, have waned sufficiently to allow the puppy to mount its own immune response. An additional booster is given at one year of age, followed by revaccination every three years in accordance with current American Animal Hospital Association (AAHA) guidelines.

In addition to vaccination, environmental management plays a role in disease prevention. Because CAV-1 is highly resistant to environmental degradation, thorough disinfection of contaminated premises is important. Steam cleaning and the use of sodium hypochlorite (bleach) at appropriate concentrations are among the most effective methods for inactivating the virus on surfaces. Contaminated outdoor areas should be considered potentially infectious for several months.

Avoiding contact with potentially infected animals and wildlife is another important preventive measure. Dogs that frequent dog parks, boarding facilities, grooming salons, or other areas where they may encounter unknown dogs should be current on their vaccinations. Dogs in rural areas where they may encounter foxes, coyotes, or other wild canids should be particularly well-protected through consistent vaccination.

Breeding facilities and shelters should implement strict vaccination protocols for all incoming animals and maintain rigorous sanitation standards. New arrivals should be quarantined and assessed before being introduced to the general population. Prompt isolation of any dog showing signs consistent with ICH can help prevent outbreaks in multi-dog environments.

Several factors influence a dog's susceptibility to infectious canine hepatitis and the likely severity of disease should infection occur. The most significant risk factor is vaccination status. Unvaccinated dogs and dogs with incomplete vaccination series are at the highest risk of contracting ICH. Puppies between six weeks and one year of age are particularly vulnerable, as maternal antibodies may have waned while their own immune system is still developing.

Age is a critical determinant of disease severity. Neonatal puppies and dogs under one year of age are more likely to develop severe or fatal forms of the disease. Older dogs with mature immune systems tend to mount more effective responses to infection, often developing only mild or subclinical disease if they have had any prior immune exposure.

Environmental and lifestyle factors also contribute to risk. Dogs housed in high-density environments such as shelters, breeding facilities, and boarding kennels face increased exposure risk due to the proximity of multiple animals and the challenges of maintaining a completely sanitized environment. Dogs in areas with large wildlife populations, particularly those with foxes and coyotes, may be exposed through environmental contamination from these reservoir hosts.

Immunocompromised dogs, whether due to concurrent disease, immunosuppressive medications, or nutritional deficiency, are at increased risk of severe disease. Dogs with pre-existing liver disease may also be more susceptible to the hepatic damage caused by CAV-1 infection. Certain breeds have not been definitively shown to have a genetic predisposition to ICH, though individual variation in immune competence can influence outcomes.

Geographic location plays a role in risk assessment. In regions with high vaccination compliance, the incidence of ICH is very low. However, in developing countries or areas with significant stray dog populations and limited access to veterinary care, the disease remains endemic and poses a substantial threat. Even in well-vaccinated populations, occasional outbreaks can occur when pockets of unvaccinated animals are exposed to the virus.

Infectious canine hepatitis can give rise to a range of acute and chronic complications affecting multiple organ systems. The most immediate and life-threatening complication is disseminated intravascular coagulation (DIC), a systemic coagulopathy triggered by widespread endothelial damage and the release of tissue factor. DIC results in simultaneous clotting and hemorrhage throughout the body and carries a high mortality rate even with aggressive treatment.

Acute hepatic failure is a direct consequence of severe CAV-1 infection and represents the primary cause of death in fatal cases. The massive hepatocellular necrosis caused by viral replication overwhelms the liver's regenerative capacity, leading to loss of synthetic, metabolic, and detoxification functions. Hepatic encephalopathy, a neurological syndrome resulting from the accumulation of toxins normally cleared by the liver, may develop in dogs with fulminant hepatic failure.

Renal complications are common, as CAV-1 has a tropism for renal tubular epithelial cells. Acute kidney injury may occur during the active phase of infection, and chronic interstitial nephritis has been documented as a long-term sequel. Dogs recovering from ICH should have renal function monitored periodically to detect any decline in kidney performance.

Ocular complications extend beyond the classic "blue eye" phenomenon. Chronic anterior uveitis, secondary glaucoma, lens luxation, and corneal ulceration have all been reported in association with ICH. These conditions may require ongoing ophthalmologic treatment and can result in permanent vision impairment if not managed appropriately.

Chronic hepatitis is perhaps the most significant long-term complication. Some dogs that survive acute ICH develop persistent hepatic inflammation that can progress to fibrosis and eventually cirrhosis. These dogs may present months or years after their initial infection with signs of chronic liver disease including weight loss, ascites, jaundice, and coagulopathy. Early detection through periodic monitoring allows for interventions that may slow disease progression.

Dogs recovering from infectious canine hepatitis require attentive care and monitoring during the convalescent period. Activity should be restricted during the initial weeks of recovery to reduce metabolic demands on the healing liver. A quiet, stress-free environment supports immune function and promotes tissue repair. Gradually increasing activity levels as the dog's energy and appetite return helps prevent deconditioning while avoiding undue strain on recovering organs.

Nutritional support is a key component of recovery management. A highly digestible, moderate-protein diet is generally recommended for dogs recovering from hepatic disease. Protein restriction was historically advocated but is now considered counterproductive unless hepatic encephalopathy is present, as adequate protein intake supports hepatic regeneration. Diets should be rich in high-quality protein sources, supplemented with B vitamins and antioxidants that support liver metabolism. Small, frequent meals are often better tolerated than large, infrequent ones.

Follow-up veterinary appointments are essential during the recovery period. Serial blood work, typically performed at two-week intervals initially and then monthly, allows the veterinarian to track liver enzyme trends and confirm that hepatic recovery is progressing normally. Persistent elevation of liver enzymes beyond the expected recovery window may indicate the development of chronic hepatitis and should prompt further diagnostic investigation, potentially including liver biopsy.

Owners should be aware of the prolonged urinary shedding period following recovery and take appropriate precautions. This includes preventing contact between the recovering dog and unvaccinated puppies or immunocompromised dogs, avoiding shared water sources in communal areas, and promptly cleaning up urine in the home environment. Informing neighbors, fellow dog owners, and boarding or daycare facilities about the shedding risk is a responsible practice.

Long-term hepatic and renal monitoring is advisable for all dogs that have experienced moderate to severe ICH. Annual or biannual blood work including a complete blood count, serum biochemistry panel, and urinalysis provides a baseline for detecting any late-onset organ dysfunction. Dogs that develop chronic hepatitis may require lifelong management with hepatoprotective supplements, dietary modification, and periodic reassessment of liver function.